{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-006911","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.473900+00:00","generated_at":"2026-05-15T21:26:40.612982+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CervoMed selects 50mg TID neflamapimod dose for Phase 3 DLB trial after Phase 1 PK study","bullets":["Phase 1 healthy volunteer study completed evaluating PK of a new stable crystal form of neflamapimod.","Selected 50mg three times per day (TID) as dosing regimen for planned Phase 3 dementia with Lewy bodies trial.","PK profile of 40mg stable crystal form largely overlaps with therapeutically active DP Batch B from Phase 2b extension.","Dose increased to 50mg TID to ensure plasma drug concentrations match those of the active batch.","New controlled manufacturing process produces only stable crystal form, mitigating prior polymorph conversion issues."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-006911","json":"https://secwatch.observer/filing/0001437749-26-006911.json","markdown":"https://secwatch.observer/filing/0001437749-26-006911.md","text":"https://secwatch.observer/filing/0001437749-26-006911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926006911/0001437749-26-006911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926006911/crvo20260304_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:26:40.612982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}